Karl-josef Kallen

Paul Ehrlich Str. 15
Tuebingen, BW 72076, Germany

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 14 publications

Phase Ib evaluation of a self-adjuvanted protamine formulated mRNA-based active cancer immunotherapy, BI1361849 (CV9202), combined with local radiation treatment in patients with stage IV non-small cell lung cancer.

Phase Ib evaluation of a self-adjuvanted protamine formulated mRNA-based active cancer immunotherapy, BI1361849 (CV9202), combined with local radiation treatment in patients with stage IV non-small cell lung cancer.

Journal: Journal for immunotherapy of cancer

Published: September 28, 2018

A phase I/IIa study of the mRNA-based cancer immunotherapy CV9201 in patients with stage IIIB/IV non-small cell lung cancer.

A phase I/IIa study of the mRNA-based cancer immunotherapy CV9201 in patients with stage IIIB/IV non-small cell lung cancer.

Journal: Cancer immunology, immunotherapy : CII

Published: July 13, 2017

Distinct transcriptional changes in non-small cell lung cancer patients associated with multi-antigenic RNActive® CV9201 immunotherapy.

Distinct transcriptional changes in non-small cell lung cancer patients associated with multi-antigenic RNActive® CV9201 immunotherapy.

Journal: Oncoimmunology

Published: August 22, 2016

A New RNA-Based Adjuvant Enhances Virus-Specific Vaccine Responses by Locally Triggering TLR- and RLH-Dependent Effects.

A New RNA-Based Adjuvant Enhances Virus-Specific Vaccine Responses by Locally Triggering TLR- and RLH-Dependent Effects.

Journal: Journal of immunology (Baltimore, Md. : 1950)

Published: June 28, 2016

Self-adjuvanted mRNA vaccination in advanced prostate cancer patients: a first-in-man phase I/IIa study.

Self-adjuvanted mRNA vaccination in advanced prostate cancer patients: a first-in-man phase I/IIa study.

Journal: Journal for immunotherapy of cancer

Published: October 31, 2014

A novel RNA-based adjuvant combines strong immunostimulatory capacities with a favorable safety profile.

A novel RNA-based adjuvant combines strong immunostimulatory capacities with a favorable safety profile.

Journal: International journal of cancer

Published: June 30, 2014

A development that may evolve into a revolution in medicine: mRNA as the basis for novel, nucleotide-based vaccines and drugs.

A development that may evolve into a revolution in medicine: mRNA as the basis for novel, nucleotide-based vaccines and drugs.

Journal: Therapeutic advances in vaccines

Published: April 24, 2014

mRNA-based vaccines synergize with radiation therapy to eradicate established tumors.

mRNA-based vaccines synergize with radiation therapy to eradicate established tumors.

Journal: Radiation oncology (London, England)

Published: March 10, 2014

Phase Ib study evaluating a self-adjuvanted mRNA cancer vaccine (RNActive®) combined with local radiation as consolidation and maintenance treatment for patients with stage IV non-small cell lung cancer.

Phase Ib study evaluating a self-adjuvanted mRNA cancer vaccine (RNActive®) combined with local radiation as consolidation and maintenance treatment for patients with stage IV non-small cell lung cancer.

Journal: BMC cancer

Published: November 29, 2013

The regulatory landscape for actively personalized cancer immunotherapies.

The regulatory landscape for actively personalized cancer immunotherapies.

Journal: Nature biotechnology

Published: October 10, 2013

A novel, disruptive vaccination technology: self-adjuvanted RNActive(®) vaccines.

A novel, disruptive vaccination technology: self-adjuvanted RNActive(®) vaccines.

Journal: Human vaccines & immunotherapeutics

Published: August 08, 2013

Developing mRNA-vaccine technologies.

Developing mRNA-vaccine technologies.

Journal: RNA biology

Published: October 16, 2012

Showing 1-12 of 14

Last Updated: 09/26/2026